SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma - Takeaways - MDSpire

SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma

  • By

  • Nicola Sgherza

  • Paola Curci

  • Rita Rizzi

  • Immacolata Attolico

  • Daniela Loconsole

  • Anna Mestice

  • Maria Chironna

  • Pellegrino Musto

  • December 14, 2021

  • 0 min

Share

  • 1

    Patients with multiple myeloma (MM) experience poorer COVID-19 outcomes, especially if older or with active disease.

  • 2

    Fully vaccinated MM patients show suboptimal antibody responses to COVID-19 vaccines, particularly those on anti-CD38 treatments.

  • 3

    Five fully vaccinated MM patients tested positive for SARS-CoV-2, highlighting the risk of breakthrough infections.

  • 4

    Infections occurred a median of 86 days post-vaccination, with variants identified including Alpha and Delta.

  • 5

    Clinical characteristics and immune responses in vaccinated MM patients require further investigation to improve outcomes.

Original Source(s)

SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma

  • by Nicola Sgherza, Paola Curci, Rita Rizzi, Immacolata Attolico, Daniela Loconsole, Anna Mestice, Maria Chironna, Pellegrino Musto

  • December 14, 2021

Related Content

Infection incidence, timing, and predictors in newly diagnosed multiple myeloma: a real-world retrospective cohort study

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min
Prognostic Impact of Early Disease Progression and Early Mortality in Patients with Multiple Myeloma: A Real-World Cohort Study